| Similar Articles |
|---|
 |
The Motley Fool
January 3, 2012
Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts.   |
The Motley Fool
June 24, 2011
Shubh Datta |
A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term. |
The Motley Fool
July 29, 2011
Shubh Datta |
A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy. |
The Motley Fool
June 30, 2011
David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
The Motley Fool
January 7, 2010
Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
CFO
March 1, 2012
David McCann |
Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies. |
The Motley Fool
December 19, 2006
Matthew Crews |
Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over. |
The Motley Fool
November 11, 2011
Dan Caplinger |
Has Walgreen Become the Perfect Stock? Given that drug retail is a low-margin business, it's improbable that Walgreen will ever reach true perfection. But with some help, improving growth numbers is a goal that could be within reach. |
The Motley Fool
January 3, 2012
Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses. |
The Motley Fool
July 6, 2007
Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note. |
The Motley Fool
March 24, 2011
Rick Aristotle Munarriz |
It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak. |
The Motley Fool
June 28, 2005
Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. |
The Motley Fool
August 31, 2011
Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool
March 22, 2010
Dave Mock |
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. |
The Motley Fool
July 5, 2005
Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool
October 5, 2011
Shubh Datta |
At Walgreen, It's Payback Time Walgreen buys back shares and raises its dividend. |
The Motley Fool
July 6, 2007
Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool
March 26, 2010
Cathy Applefeld Olson |
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup. |
The Motley Fool
July 25, 2011
Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
The Motley Fool
January 5, 2004
Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool
March 28, 2005
Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? |
The Motley Fool
June 10, 2010
Claire Stephanic |
CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers. |
The Motley Fool
March 23, 2011
Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. |
The Motley Fool
October 2, 2011
Shubh Datta |
Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment? |
The Motley Fool
October 4, 2005
Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
September 28, 2007
Timothy M. Otte |
Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth. |
The Motley Fool
August 24, 2010
David Meier |
Can Express Scripts Produce Big Returns? Express Scripts generates incredible returns on equity. Let's see how they do it. |
The Motley Fool
June 2, 2004
Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool
January 3, 2006
Stephen D. Simpson |
Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures. |
The Motley Fool
February 14, 2005
Brian Gorman |
GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision. |
The Motley Fool
March 22, 2004
Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool
December 6, 2007
Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
The Motley Fool
October 6, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Jefferies on Walgreen: Take two shares and thank me in the morning. |
The Motley Fool
September 26, 2006
Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool
March 26, 2007
Ryan Fuhrmann |
Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note. |
The Motley Fool
September 29, 2010
Andrew Bond |
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters. |
The Motley Fool
April 4, 2007
Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies. |
The Motley Fool
June 13, 2005
Brian Gorman |
Walgreen Strikes Back The traditional drugstore operator is expanding its mail-order business. This should be a welcome sign to investors. |
The Motley Fool
February 2, 2007
Ryan Fuhrmann |
Uncertain Outlook on CVS Has the retail pharmacy bit off more than it can chew? Investors may soon look back longingly to the day when CVS focused as much on organic, or internal, means to grow its business as it does on acquisitions to buy outside market share. |
The Motley Fool
July 29, 2004
Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look. |
The Motley Fool
August 1, 2007
Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one. |
The Motley Fool
September 22, 2006
Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool
January 9, 2006
Rick Aristotle Munarriz |
3 Stocks That Blew the Market Away Beat the market and the world will beat a path to your door: Constellation Brands... Monsanto... Walgreen... |
The Motley Fool
November 4, 2009
Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool
October 2, 2007
Lawrence A. Rothman |
Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future. |
The Motley Fool
January 8, 2007
Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note. |
The Motley Fool
October 7, 2010 |
DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio. |
The Motley Fool
September 27, 2004
Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool
July 26, 2010
Seth Jayson |
Show Me the Money, Walgreen All cash flow is not created equal. |
